Found 14 clinical trials
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
- 0 views
- 24 Nov, 2021
- 1 location
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.
- 0 views
- 19 Jun, 2021
- 20 locations
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies
- 18 views
- 18 Dec, 2021
- 11 locations
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21
- 2 views
- 16 Dec, 2021
- 24 locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma
designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy
- 2 views
- 29 Jan, 2021
- 54 locations
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination
- 0 views
- 19 Jul, 2021
- 2 locations
Testing the Addition of Tazemetostat to the Immunotherapy Drug Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has
- 41 views
- 10 Dec, 2021
- 27 locations
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to
- 10 views
- 07 Aug, 2021
- 31 locations
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.
- 0 views
- 12 Jan, 2022
- 7 locations
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
The primary aim of the phase 1 portion of the trial is to establish the recommended phase 2 dose (RP2D) of tazemetostat in combination with a fixed dose of pembrolizumab in patients with
- 0 views
- 01 May, 2021
- 1 location
- 1
- 2